GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ocular Therapeutix Inc (STU:0OT) » Definitions » Total Liabilities

Ocular Therapeutix (STU:0OT) Total Liabilities : €136.17 Mil (As of Dec. 2024)


View and export this data going back to 2016. Start your Free Trial

What is Ocular Therapeutix Total Liabilities?

Ocular Therapeutix's Total Liabilities for the quarter that ended in Dec. 2024 was €136.17 Mil.

Ocular Therapeutix's quarterly Total Liabilities declined from Jun. 2024 (€129.50 Mil) to Sep. 2024 (€124.65 Mil) but then increased from Sep. 2024 (€124.65 Mil) to Dec. 2024 (€136.17 Mil).

Ocular Therapeutix's annual Total Liabilities increased from Dec. 2022 (€107.53 Mil) to Dec. 2023 (€147.57 Mil) but then declined from Dec. 2023 (€147.57 Mil) to Dec. 2024 (€136.17 Mil).


Ocular Therapeutix Total Liabilities Historical Data

The historical data trend for Ocular Therapeutix's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ocular Therapeutix Total Liabilities Chart

Ocular Therapeutix Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Total Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 152.70 103.45 107.53 147.57 136.17

Ocular Therapeutix Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 147.57 120.49 129.50 124.65 136.17

Ocular Therapeutix Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Ocular Therapeutix's Total Liabilities for the fiscal year that ended in Dec. 2024 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=39.493+(70.527+12.784
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+13.37+0+0)
=136.17

Total Liabilities=Total Assets (A: Dec. 2024 )-Total Equity (A: Dec. 2024 )
=437.328-301.154
=136.17

Ocular Therapeutix's Total Liabilities for the quarter that ended in Dec. 2024 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=39.493+(70.527+12.784
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+13.37+0+0)
=136.17

Total Liabilities=Total Assets (Q: Dec. 2024 )-Total Equity (Q: Dec. 2024 )
=437.328-301.154
=136.17

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Ocular Therapeutix Total Liabilities Related Terms

Thank you for viewing the detailed overview of Ocular Therapeutix's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.


Ocular Therapeutix Business Description

Traded in Other Exchanges
Address
15 Crosby Drive, Bedford, MA, USA, 01730
Ocular Therapeutix Inc is a biotechnology company that specializes in therapies for diseases and conditions of the eye. The company uses its proprietary hydrogel platform technology to deliver therapeutic agents to the eye. Its pipeline consists of eye medication that aims to overcome the limitations of current eye-drop-based therapies for ophthalmic diseases and conditions. Its pipeline product includes Dextenza, OTX-TIC, OTX-TKI, and OTX-IVT.

Ocular Therapeutix Headlines

No Headlines